Find inexpensive medications:
Enter the name of medication below, for example 'phentermine' and press SEARCH



CMI, dosage, igredients, prescription medications, price, photoSoma

Generic name


Drug class

Centrally acting skeletal muscle relaxant

Chemical Formula


Legal status

Schedule IV

Pregnancy Category

C - Safety for use during pregnancy has not been established.

FDA approved indications

As an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Off-label & Investigational uses

Lower back pain
Carisoprodol is a centrally acting muscle relaxant is often prescribed for back pain. In several studies it was found to be superior to placebo in relieving stiffness, increasing movement, and leading to general improvement. In comparative study carisoprodol was better than propoxyphene in relieving stiffness and increasing movement. In the other comparative study carisoprodol was superior to diazepam for relieving the symptoms of acute lower back pain.

A double-blind study that compared carisoprodol, butabarbital, and placebo, has shown the effectiveness of carisoprodol in the treatment of the low back pain syndrome 4. Carisoprodol was found to be considerably more effective in providing both subjective pain relief and objective improvements in range of motion when evaluated by finger to floor testing. The results of this study suggest that the effects of carisoprodol are not secondary to its sedative effects alone, but are also related to its muscle relaxant activity.

Carisoprodol compound (carisoprodol/paracetamol/caffeine) alleviates pain, improves sleep, and minimizes the general feeling of being sick in patients with fibromyalgia.

Soma Advantages

Potent and efficient muscle relaxant
Relatively inexpensive
Rapid onset of therapeutic effect - relieves painful symptoms within 30 min.

Soma Disadvantages

Potential for drug abuse and dependence
Potential for withdrawal syndrome
May impair the mental and physical abilities required for the performance of potentially hazardous tasks such as driving.

Mode of action

Carisoprodol is a muscle relaxant that does not directly relax tense skeletal muscles in man 1. Although not well understood, the mechanism of action in humans may be related to its sedative properties, either directly or indirectly, via the effects of meprobamate.
In animals, carisoprodol produces muscle relaxation by blocking interneuronal activity in the descending reticular formation and spinal cord. However, it is unknown if this mechanism of action is also present in humans 1. Carisoprodol's primary metabolite, meprobamate, has barbiturate like modulatory effects on GABA-A receptors 9. However, it is unclear whether the GABA-A receptor-like effects are from carisoprodol itself or its metabolite meprobamate.
The pharmacological effects appear to be due to the combination of the effects of carisoprodol and meprobamate. In addition to the desired skeletal muscle-relaxing effects, carisoprodol also produces weak anticholinergic, antipyretic, and analgesic effects. High doses of carisoprodol may induce symptoms that are similar to those associated with serotonin syndrome 10.
Muscle relaxant action. It produces muscle relaxation by affecting the central nervous system. It is possible that carisoprodol induced muscle relaxation results from a slight depression of all neurons at synaptic junctions within the central nervous system. It is noteworthy that this agent has a marked depressant effect on hyperactive spinal reflexes in doses that do not affect normal reflexes.
Analgesic action. The pain-relieving properties of carisoprodol are distinctive and in certain respects are different from the actions of either the opium alkaloids, or the antipyretic-analgesics such as aspirin and paracetamol. The analgesic action of any drug may be due to its effect on:
peripheral pain receptors the sensory pain pathways and their synapses the centers concerned with pain receptors or sensory pain pathways and that it probably acts upon centers concerned with pain perception.

Potential for abuse and dependence

Case reports have established carisoprodol as a drug of abuse, but no systematic studies have been published about the extent of abuse.
It is suggested that abuse and dependence potential are due to carisoprodol’s metabolite meprobamate (federally controlled substance) 6, 15, 16. Carisoprodol undergoes hepatic biotransformation to three primary metabolites: hydroxycarisoprodol, hydroxymeprobamate, and meprobamate. The significant serum levels of meprobamate after chronic use of carisoprodol may lead to meprobarnate dependency. Withdrawal from meprobamate may result in severe reactions including seizures and coma.
One study evaluated abuse risk in patients taking carisoprodol. This study enrolled 40 patients taking carisoprodol for more than 3 months. It assessed the potential for abuse using an unvalidated six-item questionnaire and found that 20% of patients with no history of substance abuse and 65% with a history of substance abuse responded yes to one or more questions, which the authors suggested indicated a tendency towards possible abuse 6.

Soma and Alcohol interaction

Carisoprodol potentiates CNS effects of alcohol. Also, alcohol inhibits the metabolism of meprobamate and produces an additional effect on the CNS, such as sleepiness, disorientation, and confusion.

Time for Soma to clear out the system

Carisoprodol elimination half-life is 2.44 ± 0.93 hours. So, it may take 3-4 days to clear out of the system.

Onset of action

The onset of action is rapid (30 min) and lasts four to six hours.


Note: This information may not be actual at the time of reading. Always look for actual instructions in the package with the medication.
It is forbidden to use these materials without the advice of healthcare professional.

Your comments: